{"contacts": [{"terms": [{"accession": "MS:1002332", "name": "lab head"}, {"accession": "MS:1000586", "name": "contact name", "value": "Alberto Lle\u00f3"}, {"accession": "MS:1000589", "name": "contact email", "value": "Alleo@santpau.cat"}, {"accession": "MS:1000590", "name": "contact affiliation", "value": "Memory Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, 08025 Barcelona, Spain"}]}, {"terms": [{"accession": "MS:1002037", "name": "dataset submitter"}, {"accession": "MS:1000586", "name": "contact name", "value": "Cristina Chiva"}, {"accession": "MS:1000589", "name": "contact email", "value": "cristina.chiva@upf.edu"}, {"accession": "MS:1000590", "name": "contact affiliation", "value": "Proteomics Unit UPF-CRG"}]}], "description": " A thorough characterization of the synaptic component of the CSF identified 210 synaptic proteins that are detectable in human CSF. We selected an initial panel of 22 candidate biomarkers for evaluation.  In the Verification Stage, 12 proteins were discarded due to poor detection by targeted mass spectrometry (Selected Reaction Monitoring, SRM). We confirmed the expression of the remaining 10 proteins either directly at (Calsynytenin-1, GluR2, GluR4, Neurexins 2A and 3A, Neuroligin-2, Syntaxin-1B, Thy-1 and Vamp-2), or surrounding (Tenascin-R), the human synapse using Array Tomography microscopy and biochemical fractionation methods. We quantified the synaptic panel by SRM in CSF samples from 2 independent clinical cohorts of cognitively normal controls and all clinical stages of AD (n=140). A set of the panel proteins demonstrated a non-linear profile distinct to that of existing biomarkers whereby the CSF levels were decreased at the earliest preclinical stage of AD, reflecting reduced synaptic density in these asymptomatic individuals and elevated at later symptomatic stages when neurodegeneration is widespread. In conclusion, we have identified a set of novel synapse-specific proteins that could have clinical value for assessing disease progression in individuals at-risk for AD and potentially in other neurological disorders characterized by early synapse loss.", "fullDatasetLinks": [{"accession": "MS:1002873", "name": "Panorama Public dataset URI", "value": "https://panoramaweb.org/5Jugvs.url"}], "identifiers": [{"accession": "MS:1001919", "name": "ProteomeXchange accession number", "value": "PXD012138"}, {"accession": "MS:1002872", "name": "Panorama Public dataset identifier", "value": "https://panoramaweb.org/5Jugvs.url"}], "instruments": [{"accession": "MS:1000931", "name": "QTRAP 5500"}], "keywords": [{"accession": "MS:1001925", "name": "submitter keyword", "value": "Alzheimer\u2019s disease"}, {"accession": "MS:1001925", "name": "submitter keyword", "value": "cerebrospinal fluid"}, {"accession": "MS:1001925", "name": "submitter keyword", "value": "synapse"}, {"accession": "MS:1001925", "name": "submitter keyword", "value": "biomarkers"}, {"accession": "MS:1001925", "name": "submitter keyword", "value": "selected reaction monitoring"}], "modifications": [{"accession": "UNIMOD:4", "name": "Carbamidomethyl"}, {"accession": "UNIMOD:259", "name": "Label:13C(6)15N(2)"}, {"accession": "UNIMOD:267", "name": "Label:13C(6)15N(4)"}], "publications": [{"terms": [{"accession": "MS:1000879", "name": "PubMed identifier", "value": "30606734"}, {"accession": "MS:1002866", "name": "Reference", "value": "Lle\u00f3 A, N\u00fa\u00f1ez-Llaves R, Alcolea D, Chiva C, Balateu-Pa\u00f1os D, Colom-Cadena M, Gomez-Giro G, Mu\u00f1oz L, Querol-Vilaseca M, Pegueroles J, Rami L. Changes in synaptic proteins precede neurodegeneration markers in preclinical Alzheimer\u2019s disease cerebrospinal fluid. Molecular & Cellular Proteomics. 2019 Jan 1:mcp-RA118"}]}], "species": [{"terms": [{"accession": "MS:1001469", "name": "taxonomy: scientific name", "value": "Homo sapiens"}, {"accession": "MS:1001467", "name": "taxonomy: NCBI TaxID", "value": "9606"}]}], "title": "Search for synaptic biomarkers of Alzheimer\u2019s disease"}